News
Eli Lilly Revenue Soars 45% to $12.73 Billion on Obesity Drug Demand, Shares Drop After CVS Cuts Zepbound
Eli Lilly reported first-quarter revenue of $12.73 billion Thursday, a 45% increase from a year ago, driven by soaring demand for its blockbuster diabetes and weight-loss drugs, Mounjaro and Zepbound.
Eli Lilly has backed away from plans to file Alzheimer's drug donanemab in the first quarter ... results that beat expectations for both revenue and earning, thanks to a strong performance ...
AstraZeneca has axed three MedImmune legacy monoclonal antibody drugs from its neuroscience pipeline in a first-quarter clear ...
19 Apr 2025 04:23:12 GMT Eli Lilly and Company (LLY) shares rocketed 11.74% Monday after the Indianapolis-based drug manufacturer said its experimental Alzheimer’s drug significantly slowed ...
Eli Lilly has chalked up another regulatory approval for its anti-amyloid therapy for Alzheimer's disease, Kisunla, in China – the world's second-largest pharma market. The National Medical ...
Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, establishing leadership. Read more about LLY stock here.
24/7 Wall St. on MSN7d
Eli Lilly Will Be the Next $1 Trillion StockEli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback